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Abstract 
The present work explains the development and validation of a simple, rapid 
and sensitive liquid chromatographic method for the simultaneous determination 
of antipyrine (ANT), carbamazepine (CBZ), furosemide (FSD) and phenytoin 
(PHTN). Chromatographic analysis was carried out by a reversed phase 
technique on a C18 column, using water pH 3.0 and 50:50 mixtures of methanol 
and acetonitrile (58:42 v/v) as the mobile phase, at a flow-rate of 1.0 ml/min and 
a column temperature of 40°C. Detection was carried out at 205 nm for CBZ 
and PHTN and at 230 nm for ANT and FSD. The proposed method was evalu-
ated for validation parameters including linearity, range, accuracy, precision, 
limit of detection (LOD), limit of quantification (LOQ) and specificity. Elution of 
drugs ANT, FSD, PHTN, and CBZ was observed at 4.1, 5.1, 12.3 and 13.5 min, 
respectively. The method was found to be linear (R
2 ≥ 0.999) in the concen-
tration range of 5–100 μM, with an acceptable accuracy and relative standard 
deviation. Results of intra- and inter-day validation (n=3) showed the method to 
be efficient for routine determination of these permeability markers in Caco-2 
cell monolayer permeability studies. The method was successfully utilized for 
determination of standard compounds in Caco-2 permeability experiments. 90  S. R. Patil et al.:   
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Introduction 
The  Caco-2 cell monolayer is widely used for the determination of drug intestinal 
permeability and/or absorption [1–3]. According to US FDA guidance, rank order 
relationship between the Caco-2 permeability data and in-vivo human absorption data for 
at least 20 model drugs need to be established to demonstrate the method suitability of 
Caco-2 cell monolayer permeability model [4]. These drugs are selected from the class of 
high as well as low permeability drugs to demonstrate the utility of the method for both 
high as well as low permeability drugs. The present work deals with the development of an 
analytical method for simultaneous routine determination of high permeability markers – 
antipyrine (ANT), carbamazepine (CBZ), and phenytoin (PHTN) – and low permeability 
marker – furosemide (FSD). These four compounds act as internal permeability standards 
for routinely monitoring of the inter-day variability of Caco-2 cell monolayer model, as well 
as  for testing  the integrity and functioning of Caco-2 cell monolayer. Physicochemical 
properties of the four molecules are reported in Table 1. Individual analytical method for 
HPLC determination of antipyrine [5–7], carbamazepine [8–11], furosemide [12–15] and 
phenytoin [16–19] have already been reported. However, analysis by a single analytical 
method would simplify their use in cocktail approach as standard permeability markers and 
also avoid validation of analytical method for each drug [20]. The reported method can 
also be modified to suit other models for permeability study like MDCK cells or intestinal 
perfusion models.  
Materials and Methods 
Materials 
ANT and PHTN were purchased from Sigma (St. Louis, MO, USA). CBZ and FSD were a 
gift from Cadila Pharmaceuticals and IPCA laboratories Ltd. (India), respectively. HPLC 
grade acetonitrile and methanol were obtained from Mallinckrodt Baker Inc. (USA) and 
Ultrapure
® water from ELGA (Bucks, UK) was used for analysis. O-phosphoric acid and 
DMSO were from Sigma (USA). All other chemicals and reagents were of analytical or 
HPLC grade as appropriate. 
Caco-2 cells (HTB-37) were purchased from American Type Culture Collection (ATCC), 
Manassas, VA at a passage no. 18. Cells were cultured in T-75 cm
2 tissue culture flasks 
obtained from Cellstar
®, Greiner Bio-One (Germany). Hanks balanced salt solution (HBSS) 
and Dulbecco’s modified eagle’s medium (DMEM) containing 4.5 g/L glucose, L-glutamine, 
D-glucose, sodium pyruvate was obtained from Sigma, USA. Non essential amino acid 
solution (NEAA), fetal bovine serum (FBS) and trypsin-ethylenediamine tetraacetic acid 
solution were purchased from GIBCO, Invitrogen, USA. Penicillin-streptomycin-
amphotericin solution, phosphate buffered saline (PBS) and 2-[4-(2-hydroxyethyl)-1-
piperazinyl]ethanesulphonic acid (HEPES) were from HiMedia, India. Milli-Q grade water 
purified by a Milli-Q UV Purification System (Millipore, Bedford, MA, USA) was used.   Validated HPLC Method for Concurrent Determination of Antipyrine, Carbamazepine, Furosemide …  91 
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Tab. 1.   Characteristics of permeability markers used  
Drug  Structure  Molecular 
Formula  log P  pKa  BCS  
class 
Antipyrine  N
N
O
 
C11H12N2O 
(188.23 
g/mol) 
0.38  1.4  I 
(HP, HS) 
Carbamazepine  N
O NH2
 
C15H12N2O 
(223.25 
g/mol) 
2.45  14  II 
(HP, LS) 
Furosemide 
N
H
O
O H
Cl
O
S
O
O N H2  
C12H11ClN2O
5S 
(330.74 
g/mol) 
1.4  3.9  IV 
(LP, LS) 
Phenytoin 
N
H
NH O
O
 
C15H12N2O2 
(252.27 
g/mol) 
2.2  8.3  II 
(HP, LS) 
HP…high permeability; LP…low permeability; HS…high solubility; LS…low solubility. 
 
Cell culture 
Caco-2 cells were cultured in T-75 cm
2 tissue culture flask and maintained by sub-culturing 
at a split ratio of 1:4 to 1:6 when reached to 80–90% confluency. The culture medium 
contained DMEM with 1% NEAA, 1% Penicillin-streptomycin-amphotericin solution and 
15% FBS. The cells were grown in an atmosphere of 5% CO2 at 37°C and 95% humidity 
with replacement of culture medium after 2–3 days.  
For permeability studies, Caco-2 cells were seeded on a 24-well plate at a seeding density 
of 75000 cells/insert, in 0.4 μm pore size polycarbonate tissue culture inserts (Millicell
®, 
cell culture plate assembly, Millipore, Bedford, USA). Caco-2 cells were used at a passage 
of 34–40 for transport studies at 21–25 days after seeding, and the culture medium in the 
inserts (400 μl on apical side and 800 μl on basolateral side) was replaced every alternate 
day.  The trans-epithelial electric resistance (TEER), expressed in  Ohm.cm
2, was 
measured using a Millicell-ERS  voltohmmeter  (Millipore, Bedford, USA). Paracellular 
transport marker lucifer yellow was used to confirm the integrity of Caco-2 monolayers. 
Lucifer yellow was quantified at excitation and emission wavelengths of 485 nm and 530 
nm, respectively, with a spectrofluorimeter (Shimadzu, Japan). The monolayer used for the 
transport experiments had TEER values greater than 300 Ω.cm
2 and the transport rate of 
lucifer yellow was less than 1% per hour. 92  S. R. Patil et al.:   
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Transport studies 
After Caco-2 cells  were grown on filters in the  24-well plate for 21–26 days, the cell 
monolayer was washed twice with PBS pH 7.4 to remove the traces of DMEM. After 
washing, the plates were incubated with transport buffer for 30 min at 37°C in CO2 
incubator and trans-epithelial electrical resistance (TEER) of the monolayer was 
measured. TEER value was corrected by subtracting the TEER of blank inserts from 
TEER of monolayer. Transport buffer was then removed gently by aspiration. For apical to 
basolateral transport study (A→B), 400 μl of drug solution (ANT, CBZ, FSD and PHTN) in 
transport buffer was added to apical side [10] and 800 μl of blank transport buffer was 
added to the basolateral side (BL). For basolateral to apical transport study (B→A), the 
drug solution was placed on the basolateral side and blank transport buffer on the other 
side. Samples of 300 μl were withdrawn from respective compartments at 15, 30, 45, 60, 
90, and 120 min and the volume withdrawn was replaced with blank transport buffer each 
time. Experiment was performed in shaker incubator at 37°C and 75 rpm. The samples 
collected from each time point were stored at −20°C, until determined by HPLC with PDA 
detector.  
Data Analysis 
Data from three independent experiments are presented as mean±S.D. Results of bi-
directional transport are expressed as permeability coefficient (nm/s), which was 
calculated using the equation: 
Papp=
dQ/dt
A×C0
 
Where, 
dQ/dt is the slope of the cumulative drug transported vs time curve (μg/sec) 
A is the surface area of the filter (cm
2) 
C0 is the initial concentration of the drug (μM) 
Papp is the apparent permeability (cm/sec) 
Equipments/Chromatographic system 
Chromatographic measurements were performed on a Shimadzu HPLC system 
(Shimadzu, Kyoto, Japan) equipped with a model series SPD-M20A  photodiode array 
detector,  a gradient elution pump with degassing device DGU-20A5, a cooling auto-
sampler SIL-20AC, a column heater/cooler CTO-10A VP and a system controller CBM-
20A. The diode array detector was used for the spectrum extraction, while the analysis 
was carried out at 205 nm and 230 nm. Separations were performed at 35°C using a C18 
(250  mm  ×  4.6  mm,  5  μm)  stationary  phase.  Data  was  acquired  via  Class  VP  data 
acquisition software, version 6.12 SP1. AG 285 Mettler-Toledo
® balance (Switzerland) was 
used for weighing standards. In addition, Millipore filters and pH meter Cyberscan 510 
Eutech Instruments Ltd. (Singapore) were used in the study. The mobile phase solvents 
were filtered through Millipore
TM (nylon) 0.45 μm filters before use in HPLC. 
HPLC Parameters 
The chromatographic separation was carried out using a mobile phase consisting of 
Ultrapure
® water (to pH 3.0 with 20% ortho-phosphoric acid) and a mixture of acetonitrile   Validated HPLC Method for Concurrent Determination of Antipyrine, Carbamazepine, Furosemide …  93 
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and methanol in 50:50 ratio at an isocratic mode with 58:42 proportions. The injection 
volume was 10 μl, and the mobile-phase flow rate was set to 1 ml min
−1. Detection was 
carried out at 205 nm for CBZ and PHTN and at 230 nm for ANT and FSD.  
Standard and sample preparation 
Primary stock solution of all drugs, i.e., ANT, CBZ, FSD, and PHTN was prepared in 
methanol to obtain a concentration of 10 mM. Consequently, the primary stock solution 
was diluted with HBSS buffer to prepare a secondary stock solution of 100 µM 
concentration. Secondary stock solution was diluted with HBSS to achieve concentrations 
in the range of 5–100 µM. 
Validation Studies 
The proposed HPLC method was validated for various parameters, viz. linearity, range, 
specificity, sensitivity, accuracy, precision, limit of detection (LOD) and limit of 
quantification (LOQ). The developed method was validated according to ICH guidelines for 
linearity, accuracy and precision, and specificity [21, 22]. 
Peak purity of all the drugs in HBSS buffer was assessed through the study of purity plots 
using PDA detector. Linearity of the method was evaluated from the standard curve of the 
detector response (peak area) against drug concentration. Calibration curve (n=3) with 
eight concentrations was plotted in the range of 5-100 µM. Peak areas of the drug versus 
concentration were plotted and found to be linear in the entire concentration range.  
Accuracy and precision were determined with six replicates of quality control (QC) 
samples. QC samples were prepared in blank HBSS samples, at three concentrations of 
10, 40, and 80 μM, following the same procedure as reported for calibration standards and 
using a different primary stock. Calibration curves were prepared thrice on the same day to 
assess the intra-day variation, and the inter-day variability was checked by constructing 
calibration curves on three consecutive days. Samples were analyzed at three different 
concentrations, in triplicate, within the calibration range (n=6).The results were expressed 
as percent relative standard deviation (% RSD) of concentration.  
To determine the robustness of the developed method, experimental conditions were 
altered deliberately and the resolution between the drugs was recorded. The flow rate of 
the mobile phase was 1 ml/min. To study the effect of flow rate on the resolution, the flow 
rate was changed by 0.2 units from 0.8 to 1.2 ml per min. The effect of column 
temperature on resolution was studied at 35 and 45°C instead of 40°C. Also, the resolution 
of the drug was studied by performing the analyses on a different chromatographic system 
to establish the robustness of the method. 
Result and Discussion 
Method Development 
Method development was initiated with aqueous phase and acetonitrile in 50:50 v/v 
proportions. Firstly, aqueous phase adjusted with buffers to various pH values, viz., pH 3.0 
(phosphate buffer), 5.0 (acetate buffer) and 7.0 (phosphate buffer) were tried. However, 
acceptable results in terms of peak resolution could not be obtained. Thereafter, water 
adjusted to pH 3.0, 3.5, 4.0 and 5.0, with phosphoric acid in 50:50 proportion with aceto-94  S. R. Patil et al.:   
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nitrile was tried and a pH of 3.0 was chosen for further method development. The effect of 
pH was most prominent on FSD than on other drugs and at pH 5.0, FSD showed a doublet 
of equal intensity with peaks of the other drugs being unaffected. 
Adjustment to pH 3.0 was tried using different acidifiers viz. trifluroacetic acid, hydrochloric 
acid, glacial acetic acid and phosphoric acid, but only the latter could separate all the 
drugs with good resolution and peak intensity. However, the resolution of peak was not 
optimal, with acetonitrile alone as the organic medium. Replacement of acetonitrile with 
methanol also could not improve the resolution. Thereafter, to improve the resolution and 
peak shape, mixtures of varying proportions of methanol and acetonitrile were tried, 
alongwith an aqueous phase adjusted to pH 3.0 with phosphoric acid. Thus, 50:50 v/v ratio 
of acetonitrile:methanol was finalized for further development. Increase in the concen-
tration of either acetonitrile or methanol alone resulted in unresolved peaks and/or tailing, 
respectively. Concentration of  the organic content (50:50 acetonitrile:methanol) in the 
mobile phase was varied from 20% to 50%, which led to selection of 40% v/v organic 
phase (50:50 acetonitrile:methanol), in combination with water pH 3.0 (60% v/v). Further 
optimization resulted in ratio of 58:42 v/v of water pH 3.0 and mixture of acetonitrile and 
methanol (50:50 v/v), respectively. However, application of a gradient method to further 
shorten the duration was unsuccessful, as it led to loss of resolution between the adjacent 
drug peaks. 
Stability of analytical solutions  
Drug solutions of 100 μM (in triplicate) were kept in HBSS buffer for 24 h for bench-top 
stability study and analyzed using the same method. The results showed not less than 99 
% of the drug remained in solution after 24 h (data not shown). 
Method Validation 
Peak purity assessment 
Peak purity evaluation was performed with the objective of obtaining supportive 
information during selection of appropriate analytical conditions for specific determination 
of permeability markers. Peaks corresponding to the drug showed positive value for the 
minimum peak purity index over the entire range of integrated peak indicating their purity. 
Tab. 2.   Validation parameters of the HPLC method for ANT, CBZ, FSD and PHTN 
Parameter  Value 
ANT  CBZ  FSD  PHTN 
Analytical wavelength  230 nm  205 nm  230 nm  205 nm 
Range (μM)  5–100  5–100  5–100  5–100 
Slope  
(Mean ±S.D; R.S.D.) 
7668.8  
± 103.3; 1.3 
16075.5  
± 39.3; 0.24 
22085.1  
± 149.0; 0.67 
13577.6  
± 18.19; 0.13 
Intercept  
(Mean ± S.D.) 
−5541.3  
± 172.8 
−3746.8  
± 66.91 
1426.1  
± 191.9 
−3443.4  
± 386.1 
Regression coefficient  0.999  1.000  0.999  1.000 
LOD (µM)  3.28  0.67  0.13  0.73 
LOQ (µM)  5.28  2.24  0.58  2.04 
Each standard curve was generated in triplicate on 3 consecutive days, across the linearity range. 
Values are reported as mean±SD of three calibration curves.   Validated HPLC Method for Concurrent Determination of Antipyrine, Carbamazepine, Furosemide …  95 
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Tab. 3.  Data of linearity studies for ANT, CBZ, FSD, and PHTN 
Conc. 
(μM) 
Mean Peak Area ± S.D., R.S.D. (%) 
ANT  CBZ  FSD  PHTN 
5  33934.5  
± 130.8; 0.38 
73873.3  
± 666.3;   0.91 
106796.3  
± 1187.9; 1.11 
61020.0  
± 400.2;   0.65 
10  74048.5  
± 1948.1; 2.63 
159297.5 
± 4349.4; 2.73 
220881.0  
± 5107.4; 2.31 
132452.5  
± 1699.2; 1.28 
20  147243.0  
± 861.25; 0.58 
314557.3 
± 1862.6; 0.59 
443556.3  
± 1103.3; 0.25 
264798.0  
± 625.1;   0.24 
30  225102.5 
± 1723.2; 0.76 
483318.7  
± 2727.5; 0.56 
677090.7  
± 1529.9; 0.22 
407881.0  
± 1223.3; 0.29 
40  297507.0  
± 381.8; 0.13 
644809.0 
± 1289.9; 0.20 
900838.7  
± 2264.2; 0.25 
544944.5  
± 1320.2; 0.24 
60  459703.0  
± 445.9; 0.09 
966179.0  
± 5876.6; 0.61 
1341402.0  
± 1512.6; 0.11 
814444.0  
± 1694.2; 0.21 
80  614150.3  
± 1137.8; 0.18 
1274946.0  
± 3176.9; 0.25 
1773965.0  
± 2945.5; 0.17 
1076016.0  
± 2026.6; 0.19 
100  776083.0  
± 76.4; 0.01 
1612014.0  
± 6691.5; 0.41 
2223262.0  
± 4658.7; 0.21 
1358006.0  
± 653.4;   0.05 
Equ.  y = 7765.3x  
− 5694 
y = 16113x  
− 3773 
y = 22256x  
+ 1535.3 
y = 13596x  
− 3881 
(r
2)  0.999  1.000  0.999  1.000 
 
Specificity and Sensitivity 
Specificity of a method can be defined as absence of any interference at retention times of 
peaks of interest and is evaluated by observing the chromatograms of blank samples and 
calibration samples spiked with drug. Specificity is the ability of the analytical method to 
measure accurately and specifically the analyte of interest in the presence of other 
components that might be expected to be present in the sample matrix. The representative 
chromatograms of ANT, CBZ, FSD, and PHTN are presented as shown in  Figure 1. 
Interfering peaks of any endogenous buffer are not observed near the retention times of 
these drugs. The retention times of ANT, FSD, PHTN, and CBZ were 4.1, 5.1, 12.3 and 
13.5 min,  respectively.  The method specificity was assessed by comparing the 
chromatograms obtained from drugs alone, mixture of drug samples and through the peak 
purity curves.  
The sensitivity of a method is represented by the values of limit of detection (LOD) and 
limit of quantification (LOQ). The lowest concentration of the drug detectable by the 
proposed method is termed as LOD, while LOQ is the minimum quantifiable concentration 
of the drug by the suggested method. The values of LOD and LOQ were computed by 
using the formula for detection limit as DL= 3 σ/S and for quantitation limit as QL=10 σ/S. 
The LOQ calculated using this formula was found to be 5.28 µM for ANT, 2.24 µM for 
CBZ, 0.58 µM for FSD and 2.04 µM for PHTN. The validation parameters including LOD 
and LOQ are shown in Table 2.  
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Linearity and Range 
Table 3 shows the data for the determination of linearity and range for determination of 
ANT, CBZ, FSD and PHTN. As shown, the responses for the drugs were obtained to be 
strictly linear in the concentration range of 5–100 µg/ml. The standard curve had a reliable 
reproducibility over the concentrations of drugs across the calibration range. 
Accuracy and Precision 
Accuracy and precision of the method represents the repeatability and robustness of the 
analytical method and was determined by analyzing the QC samples. Good recoveries 
were obtained for each concentration used, confirming that the method was accurate, as 
shown in Table 4. Acceptable relative standard deviation (R.S.D.) limits indicated that the 
method is accurate and precise for the designated application. 
Tab. 4.  Result of specificity study 
Conc.  
(μM) 
ANT  FSD 
Conc. ± S.D., R.S.D. (%)  %R  Conc. ± S.D., R.S.D. (%)  %R 
10  10.145 ± 0.137; 1.35  101.45  9.955 ± 0.095; 0.95  99.55 
40  39.805 ± 0.367; 0.92  99.51  40.186 ± 0.124; 0.31  100.46 
80  80.192 ± 0.444; 0.55  100.24  79.960 ± 0.137; 0.17  99.95 
Conc.  
(μM) 
PHTN  CBZ 
Conc. ± S.D., R.S.D. (%)  %R  Conc. ± S.D., R.S.D. (%)  %R 
10  9.929 ± 0.137; 1.38  99.29  10.123 ± 0.172; 1.70  101.23 
40  40.137 ± 0.136; 0.34  100.34  40.209 ± 0.136; 0.34  100.52 
80  79.826 ± 0.266; 0.33  99.78  79.833 ± 0.223; 0.28  99.79 
%R… % recovery. 
 
Tab. 5.  Precision studies (n = 6) 
Spiked  
Conc. (μM) 
Measured Concentration ± S.D., R.S.D. (%) 
ANT  FSD  PHTN  CBZ 
Inter-day precision 
10  10.247  
± 0.183; 1.78 
10.041  
± 0.087; 0.86 
9.936  
± 0.045; 0.45 
10.114  
± 0.125; 1.23 
40  40.025  
± 0.645; 1.61 
40.589  
± 0.248; 0.61 
40.318  
± 0.286; 0.711 
40.252  
± 0.254; 0.63 
80  79.787  
± 0.916; 1.14 
80.007 
± 0.389; 0.48 
79.706  
± 0.402; 0.50 
79.795 
± 0.552; 0.69 
Intra-day precision 
10  10.374 
± 0.068; 0.66 
10.015 
± 0.03; 0.31 
9.965  
± 0.026; 0.26 
10.183 
± 0.115; 1.13 
40  39.610  
± 0.189; 0.47 
40.748  
± 0.131; 0.32 
40.387  
± 0.121; 0.29 
40.217  
± 0.152; 0.37 
80  79.803  
± 0.326; 0.41 
80.256  
± 0.267; 0.33 
79.647  
± 0.128; 0.16 
79.661  
± 0.126; 0.15 
   Validated HPLC Method for Concurrent Determination of Antipyrine, Carbamazepine, Furosemide …  97 
Sci Pharm. 2012; 80: 89–100 
Robustness 
Resolution of the drugs in a mixture was found to be similar as in Figure 1, when studies 
were performed under deliberately altered conditions, indicating that the method had high 
robustness.  Inter-day and intra-day calibration curves demonstrated the intermediate 
precision of the method and expressed as percent RSD for a statistically significant 
number of samples (n=6). The % RSD values in the regression lines prepared on the 
same day or different days were within the limits (Table 5).  
 
Fig. 1.   Chromatogram of ANT, CBZ, FSD and PHTN from mixture (100 μM) and blank 
HBSS buffer (lower) at 205 nm and 230 nm 
Application of method in determining Caco-2 permeability of markers  
Permeability study of ANT, CBZ, FSD and PHTN (n ≥ 5) was carried out using Caco-2 cell 
monolayer grown on a polycarbonate filter for 21–25 days. The mean apparent 
permeability values (cm/s) of FSD, ANT, CBZ and PHTN were found to be 5.4 x 10
−6, 
106.9 x 10
−6, 209.2 x 10
−6  and 32.8 x 10
−6, respectively, showing that FSD is a low 
permeability drug [23], and ANT [4], CBZ [24] and PHTN [25] belong to the category of 
high permeability drugs, as stated in the literature. The method is currently being routinely 
employed for analysis of markers for Caco-2 permeability studies. 98  S. R. Patil et al.:   
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Conclusion 
Assessment of in-vitro Caco-2 permeability requires simultaneous quantitation of high and 
low permeability markers to ascertain the suitability of the method. This study represents a 
simple, rapid and reliable validated RP-HPLC method for the quantification of ANT, CBZ, 
FSD and PHTN in presence of HBSS buffer with a relatively short run time. The developed 
method is highly specific, accurate and precise, making it suitable for the routine analysis 
of these permeability markers in Caco-2 permeability study. 
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